REPORT
EXCLUSIVE LIFE SCIENCE FEATURE
20
LIFESCIENCELEADER.COM JULY 2014 CMO SUPPLEMENT
The latest industry trends and proprietary data from Nice Insight survey results
The drug development industry is motivated to invest in developing biopharmaceuticals
as a form of pipeline security because these products have demonstrated prof tability.
The practice of partnering with or acquiring biopharmaceutical companies is mirrored
in the results of the Nice Insight Pharmaceutical and Biotechnology Outsourcing
survey, where 73 percent of respondents stated the company they work for engages in
the development of biologics-based therapeutics. These respondents will spend more
than half of their outsourcing budget on the development of biologics — 57 percent
compared to 43 percent of the outsourcing budget spent on conventional therapeutics.
0 7 1 4 _ R e s e a r c h _ R e p o r t s _ O I _ B i o 2 . i n d d 1 0714_Research_Reports_OI_Bio2.indd 1 6 / 2 0 / 2 0 1 4 1 : 2 2 : 5 7 P M 6/20/2014 1:22:57 PM